NEUP

+ Watchlist + Portfolio

Neuphoria Therapeutics Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.51
52-Week Range: $3.19 – $21.40
Market Cap: $18.78M
P/E (TTM): —
EPS (TTM): -3.06
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.63
PEG Ratio: —
Return on Equity: -61.70%
Return on Assets: -19.66%
Gross Margin: 100.00%
Operating Margin: -15.66%
Profit Margin: 0.00%
Current Ratio: 27.85
Debt/Equity: 0.00
Total Debt: $34.34K
Free Cash Flow: $-8.34M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-1.05M

NEUP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$181.36K	$0.00	$0.00	—	$1.17M
Research & Development	$11.01M	$13.07M	$9.42M	—	$3.55M
Selling, General & Admin	—	$8.91M	$8.47M	—	$7.44M
Operating Expenses	$14.86M	$21.56M	$17.80M	—	$10.18M
Operating Income	-$14.68M	-$21.56M	-$17.80M	—	-$9.01M
EBITDA	-$14.32M	-$20.90M	-$17.13M	—	-$8.35M
Pretax Income	-$15.10M	-$21.52M	-$15.58M	—	-$13.59M
Income Tax	-$131.95K	-$139.17K	-$87.32K	—	-$139.17K
Net Income	-$14.97M	-$21.38M	-$15.49M	—	-$13.45M
Diluted EPS	-0.17	-0.16	-18.62	-0.23	—
Diluted Shares	1.35B	122.39M	832225	1.62M	—

NEUP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	—	$23.09M	$12.10M	$12.61M	$19.87M
Receivables	—	$4.67M	$426.09K	$126.88K	$813.43K
Current Assets	—	$28.76M	$13.33M	$13.19M	$21.07M
Total Assets	—	$44.93M	$28.56M	$27.65M	$28.71M
Current Liabilities	—	$2.31M	$2.74M	$3.83M	$756.58K
Total Debt	—	$477.15K	$386.92K	$272.74K	$34.34K
Total Liabilities	—	$5.78M	$6.55M	$10.16M	$4.11M
Retained Earnings	—	-$119.22M	-$162.48M	-$177.98M	-$191.80M
Shareholders' Equity	—	$39.15M	$22.01M	$17.49M	$24.60M
Working Capital	—	$26.45M	$10.59M	$9.36M	$20.31M

NEUP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	—	-$14.64M	-$14.68M	—	-$12.35M
Free Cash Flow	—	-$14.64M	-$14.68M	—	-$12.35M
Depreciation & Amortisation	—	$663.19K	$662.99K	—	$662.96K
Stock-Based Compensation	—	$1.35M	$814.81K	—	$351.60K
Investing Cash Flow	—	$317.41K	—	—	—
Financing Cash Flow	—	$3.86M	$15.11M	—	$17.92M
Net Change in Cash	—	-$10.78M	$428.02K	—	$5.56M

NEUP Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$662.72K	$15.00M	$0.00	$0.00	$0.00	$1.17M
Research & Development	$1.74M	$1.62M	$3.79M	$697.72K	-$518.17K	-$419.78K
Selling, General & Admin	$2.63M	$1.41M	$1.87M	$2.13M	$1.69M	$1.76M
Operating Expenses	$4.06M	$3.03M	$5.65M	$2.35M	$827.28K	$1.36M
Operating Income	-$3.40M	$11.97M	-$5.65M	-$2.35M	-$827.28K	-$183.92K
EBITDA	-$3.23M	$12.14M	-$5.49M	-$2.18M	-$661.59K	-$18.24K
Pretax Income	-$1.93M	$11.18M	-$9.94M	$1.83M	-$539.86K	-$4.94M
Income Tax	$11.61K	-$81.19K	-$34.79K	-$34.79K	-$34.79K	-$34.79K
Net Income	-$1.94M	$11.26M	-$9.91M	$1.86M	-$505.06K	-$4.90M
Diluted EPS	-1.79	6.55	-4.41	-0.77	-0.09	—
Diluted Shares	1.58M	1.72M	2.25M	4.54M	5.41M	—

NEUP Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$4.34M	$17.04M	$13.65M	$22.17M	$19.44M	$19.87M
Receivables	$35.56K	$24.59K	$1.76K	$1.11M	$1.61M	$813.43K
Current Assets	$4.40M	$17.09M	$13.95M	$23.39M	$21.66M	$21.07M
Total Assets	$18.17M	$30.71M	$27.34M	$36.60M	$34.81M	$28.71M
Current Liabilities	$2.13M	$1.55M	$5.12M	$2.59M	$1.51M	$756.58K
Total Debt	$199.40K	$172.46K	$118.22K	$33.47K	$34.23K	$34.34K
Total Liabilities	$4.42M	$4.72M	$14.83M	$6.90M	$5.39M	$4.11M
Retained Earnings	-$180.73M	-$169.46M	-$188.25M	-$186.39M	-$186.89M	-$191.80M
Shareholders' Equity	$13.75M	$26.00M	$12.51M	$29.70M	$29.42M	$24.60M
Working Capital	$2.26M	$15.54M	$8.83M	$20.80M	$20.14M	$20.31M

NEUP Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.36M	$11.45M	-$3.79M	-$6.44M	-$3.34M	$1.21M
Free Cash Flow	-$3.36M	$11.45M	-$3.79M	-$6.44M	-$3.34M	$1.21M
Depreciation & Amortisation	$166.12K	$165.43K	$165.79K	$165.79K	$165.69K	$165.68K
Stock-Based Compensation	$19.08K	$19.68K	$111.28K	$93.70K	$70.29K	$76.34K
Financing Cash Flow	-$111.56K	$1.16M	$3.25M	$14.66M	$0.00	$0.00
Net Change in Cash	-$3.47M	$12.62M	-$541.03K	$8.23M	-$3.34M	$1.21M

Market Snapshot

About

Neuphoria Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric disorders. The company focuses on innovative therapies for conditions such as depression, anxiety, and other mental health disorders using proprietary drug candidates and delivery mechanisms.